Mind Medicine (MNMD) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MindMed has appointed Gregg A. Pratt, Ph.D., as the Chief Regulatory and Quality Assurance Officer to enhance their regulatory capabilities and expedite progress in launching Phase 3 studies for treatments targeting anxiety and depressive disorders. This move aims to leverage Dr. Pratt’s expertise in securing approvals for groundbreaking psychiatric drugs, including a novel schizophrenia treatment.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
